This is a study of a new drug (CN105) that has not yet been approved for use in the general population by the FDA. This drug is being used to treat intracranial hemorrhage patients. We are studying the effects of this drug given to these patients to make sure that the drug is safe. This is an important step that all new drugs must go through before they are approved for use by the FDA. To determine if this drug is safe, we will be following the outcomes of patients that receive this new drug for the first 90 days after receiving it.
To assess whether deferoxamine mesylate (DFO) provides any benefit in individuals who suffer a spontaneous intracerebral hemorrhage (ICH). This study
will compare the outcomes of participants treated with deferoxamine mesylate (DFO) to those treated with a placebo.